NAVIDEA BIOPHARMACEUTICALS I (NAVB)
US63937X2027 - Common Stock
NAVIDEA BIOPHARMACEUTICALS I
NYSEARCA:NAVB (10/5/2023, 8:04:00 PM)
0.0779
0 (-2.99%)
Company Profile
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. The company is headquartered in Dublin Ohio, Ohio and currently employs 11 full-time employees. The firm is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. The company has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).
Company Info
NAVIDEA BIOPHARMACEUTICALS I
Suite 300, 425 Metro Place North
Dublin Ohio OHIO 43017
P: 16147937500.0
CEO: Jed A. Latkin
Employees: 11
Website: https://www.navidea.com/
NAVB News
7 months ago - Navidea Biopharmaceuticals, Inc.Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 20247 months ago - Navidea Biopharmaceuticals, Inc.Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024a year ago - Navidea Biopharmaceuticals, Inc.Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligationsa year ago - Seeking AlphaNavidea settles litigation with Capital Royalty, stock rallies 30% (NAVB)Navidea Biopharmaceuticals (NAVB) and Capital Royalty Partners have entered into a binding agreement and mutual release to settle their long-running litigation. Read more here.
a year ago - Navidea Biopharmaceuticals, Inc.Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Releasea year ago - Navidea Biopharmaceuticals, Inc.Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common StockNAVB Twits
Here you can normally see the latest stock twits on NAVB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
